Taking part in screening research
I first came across the ELSA study when I was scrolling on social media in late 2023. Having type 1 diabetes, I knew that Imogen would have a higher risk herself and at the back of my mind I’d always thought – ‘is this going to be part of her journey?’. So, I signed her up straight away.
The pack came in the post with a finger-prick blood test kit. We did it, sent it off, and then honestly forgot about it.
Two or three months later I got a call from a member of the ELSA team. They explained that Imogen had some of the protein markers in her blood that they test for, called autoantibodies. But we’d need to visit a hospital to have a further blood test to confirm the results and find out how many autoantibodies Imogen had. That would tell us more about her future risk.
We got a phone call with those results a few weeks later while Imogen and I were in the supermarket car park together. The nurse on the call explained Imogen had three autoantibodies and that meant she was going to get type 1 diabetes at some point in the future. Imogen was so calm about it – she said to me, 'That's OK, can we go and get some chocolate now?'
